Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this randomized, double-blind, placebo-controlled multicenter study is to
determine in a cohort of 506 patients with acute ischemic stroke in the middle cerebral
artery territory, the effect of a three-day high-dose, intravenous erythropoietin treatment
on functional outcome up to a follow-up of 90 days.